These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 14751129)
1. What is the clinical value of adding tamoxifen to progestins in the treatment [correction for treament] of advanced or recurrent endometrial cancer? Herzog TJ Gynecol Oncol; 2004 Jan; 92(1):1-3. PubMed ID: 14751129 [No Abstract] [Full Text] [Related]
2. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Fiorica JV; Brunetto VL; Hanjani P; Lentz SS; Mannel R; Andersen W; Gynecol Oncol; 2004 Jan; 92(1):10-4. PubMed ID: 14751131 [TBL] [Abstract][Full Text] [Related]
3. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Fleming GF; Filiaci VL; Marzullo B; Zaino RJ; Davidson SA; Pearl M; Makker V; Burke JJ; Zweizig SL; Van Le L; Hanjani P; Downey G; Walker JL; Reyes HD; Leslie KK Gynecol Oncol; 2014 Mar; 132(3):585-92. PubMed ID: 24456823 [TBL] [Abstract][Full Text] [Related]
4. Hormonal treatment of endometrial cancer: past, present and future. Podczaski E; Mortel R Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):469-89. PubMed ID: 11476566 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Whitney CW; Brunetto VL; Zaino RJ; Lentz SS; Sorosky J; Armstrong DK; Lee RB; Gynecol Oncol; 2004 Jan; 92(1):4-9. PubMed ID: 14751130 [TBL] [Abstract][Full Text] [Related]
7. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887 [TBL] [Abstract][Full Text] [Related]
8. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. Thigpen JT; Brady MF; Alvarez RD; Adelson MD; Homesley HD; Manetta A; Soper JT; Given FT J Clin Oncol; 1999 Jun; 17(6):1736-44. PubMed ID: 10561210 [TBL] [Abstract][Full Text] [Related]
9. [Chemotherapy in metastatic or recurrent endometrial carcinoma]. Deppe G; Baumann P; Munkarah A Zentralbl Gynakol; 2000; 122(7):355-60. PubMed ID: 10951705 [TBL] [Abstract][Full Text] [Related]
10. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Seong SJ; Kim TJ; Kim JW; Kim SM; Bae DS; Nam JH Eur J Cancer; 2013 Mar; 49(4):868-74. PubMed ID: 23072814 [TBL] [Abstract][Full Text] [Related]
11. Hormonal therapy for women with stage IA endometrial cancer of all grades. Park JY; Kim DY; Kim TJ; Kim JW; Kim JH; Kim YM; Kim YT; Bae DS; Nam JH Obstet Gynecol; 2013 Jul; 122(1):7-14. PubMed ID: 23743459 [TBL] [Abstract][Full Text] [Related]
12. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Pandya KJ; Yeap BY; Weiner LM; Krook JE; Erban JK; Schinella RA; Davis TE Am J Clin Oncol; 2001 Feb; 24(1):43-6. PubMed ID: 11232948 [TBL] [Abstract][Full Text] [Related]
13. Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor. Leiser AL; Hamid AM; Blanchard R Gynecol Oncol; 2004 Aug; 94(2):567-71. PubMed ID: 15297205 [TBL] [Abstract][Full Text] [Related]
14. A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer. Pautier P; Vergote I; Joly F; Melichar B; Kutarska E; Hall G; Lisyanskaya A; Reed N; Oaknin A; Ostapenko V; Zvirbule Z; Chetaille E; Geniaux A; Shoaib M; Green JA Int J Gynecol Cancer; 2017 Feb; 27(2):258-266. PubMed ID: 27870712 [TBL] [Abstract][Full Text] [Related]
15. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Singh M; Zaino RJ; Filiaci VJ; Leslie KK Gynecol Oncol; 2007 Aug; 106(2):325-33. PubMed ID: 17532033 [TBL] [Abstract][Full Text] [Related]
16. Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer. He Y; Wang Y; Zhou R; Wang J Int J Gynecol Cancer; 2020 Dec; 30(12):1902-1907. PubMed ID: 33051245 [TBL] [Abstract][Full Text] [Related]
17. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Gadducci A; Cosio S; Genazzani AR Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330 [TBL] [Abstract][Full Text] [Related]
18. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer. Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012 [TBL] [Abstract][Full Text] [Related]
19. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Wang CB; Wang CJ; Huang HJ; Hsueh S; Chou HH; Soong YK; Lai CH Cancer; 2002 Apr; 94(8):2192-8. PubMed ID: 12001117 [TBL] [Abstract][Full Text] [Related]
20. Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: a phase II study. Pinelli DM; Fiorica JV; Roberts WS; Hoffman MS; Nicosia SV; Cavanagh D Gynecol Oncol; 1996 Mar; 60(3):462-7. PubMed ID: 8774658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]